- Clene recently participated in the Mizuho Neuroscience Summit 2024, the Benchmark 2024 Healthcare House Call Virtual Conference, and the Virtual A.G.P. Healthcare Conference
- CNM-Au8(R) is oral suspension developed to restore neuronal health and function by increasing energy production and utilization
- The therapy has been involved in clinical trials and compassionate use programs, accumulating over 600 years of exposure across various neurodegenerative conditions, with no safety concerns reported
Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”), and Parkinson’s disease, recently participated in three investor conferences during May – The Mizuho Neuroscience Summit 2024, the Benchmark 2024 Healthcare House Call Virtual Conference, and the Virtual A.G.P. Healthcare Conference. These conferences provided Clene with the opportunity to present its lead drug candidate CNM-Au8(R), an oral suspension developed to restore neuronal health and function by increasing energy production and utilization.
The Mizuho Neuroscience Summit 2024 took take place on May 20-21 at the Boston Harbor Hotel in Boston, MA (https://ibn.fm/yVw8Y). This event, organized by Mizuho Americas, is part of their initiative to explore promising investment trends and breakthroughs in the field of neuroscience. The summit included panel presentations and opportunities for one-on-one meetings, providing a platform for leading medical experts and biopharmaceutical companies to discuss advancements in treating neurodegenerative and psychiatric diseases.
The inaugural summit in 2023 focused on key topics such as Alzheimer’s disease treatment, neurodegenerative diseases, and emerging psychiatric treatments, featuring insights from top venture capital investors and biotech markets. This kind of event is crucial as it brings together expertise from various areas of neuroscience to foster discussions that could lead to new collaborations and innovations in the field.
The Benchmark 2024 Healthcare House Call Virtual Conference occurred May 21-22, 2024 (https://ibn.fm/nsz6r). This virtual event was designed to facilitate one-on-one meetings between participants, offering a direct and personalized way to engage with healthcare experts and professionals. The format of this conference supports in-depth discussions and networking opportunities in a virtual setting, making it accessible for a wide audience regardless of geographic location. This event is part of a broader series of conferences that focus on the healthcare sector, providing insights and updates on various healthcare topics and trends.
The Virtual A.G.P. Healthcare Conference took place May 22, 2024 (https://ibn.fm/pkTaR). This conference was set up as a virtual event, providing a platform for participants to engage in one-on-one meetings with healthcare professionals, investors, and industry experts. The virtual format of this conference is particularly designed to cater to a global audience, enabling stakeholders from various parts of the world to connect, share insights, and discuss the latest trends and developments in the healthcare sector without the need for travel.
The company’s presentation about CNM-Au8 showcased it as an innovative treatment involving a suspension of gold nanocrystals aimed at addressing neurodegeneration. It works by targeting the core issues prevalent in diseases like ALS, MS, and Parkinson’s—specifically mitochondrial dysfunction, NAD+ decline, and oxidative stress. Its catalytic action helps maintain cell metabolism, reduce harmful reactive oxygen species, and promote protein homeostasis, thereby offering neuroprotective and remyelinating benefits.
The therapy has been involved in clinical trials and compassionate use programs, accumulating over 600 years of exposure across various neurodegenerative conditions, with no safety concerns reported. This highlights its potential as a safe adjunct to other treatments, enhancing cell function and survival, particularly noted in clinical ALS trials.
For more information, visit the company’s website at www.Clene.com.
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is powered by IBN